Abiopharma

🔍 Hamill John P. (Executive)

Company: Aprea Therapeutics, Inc. (APRE)

Report Date: 2025-12-10

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $1.165 per share (Direct)
  Date: 2025-12-10 | Code: P | equity_swap_involved: 0 | shares_owned_after: 27,733.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,000 shares of Common Warrant at $1.04 per share (Derivative)
  Date: 2025-12-10 | Code: P | Exercise: 2025-12-10 | equity_swap_involved: 0 | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 an aggregate of 5,000 shares of the Issuer's common stock ("Shares") at a purchase price of $1.165. The Reporting Person also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 5,000 Shares.
• F2: The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.
• F3: The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.